Market Overview:
The global ulcerative colitis treatment market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of ulcerative colitis, increasing awareness about the disease, and technological advancements in the field of ulcerative colitis treatment. The global ulcerative colitis treatment market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into anti-inflammatory drugs, immune system suppressors, and other medications. Anti-inflammatory drugs are further subsegmented into traditional NSAIDs and COX-2 inhibitors. Immune system suppressors are further subsegmented into corticosteroids and immunosuppressants. Other medications are further subsegmented into antibiotics and biologics/biosimilars. On the basis of application, it is segmented into hospital settings (inpatient/outpatient), clinic settings (primary care physicians/specialists), drug stores (pharmacies/retail outlets), and others (research institutes/academic institutions). Geographically, it is segmented into North America, Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Ulcerative colitis treatment is the process of managing and curing the symptoms of ulcerative colitis. It is important to manage and treat ulcerative colitis because it can cause long-term damage to the digestive system and lead to other health problems if not properly treated.
Anti-inflammatory Drugs:
Anti-inflammatory drugs are the drugs that reduce inflammation by decreasing prostaglandins and leukotrienes. They can be used for treatment of rheumatoid arthritis, osteoarthritis, Crohn's disease, psoriasis and other diseases. The global anti-inflammatory drug market was valued at over USD 20 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period.
Immune System Suppressors:
Immune system suppressors are substances that act as immune-modulating agents. They work by decreasing the activity of the immune system. Some of these products are also used to treat cancer and autoimmune diseases, such as rheumatoid arthritis and lupus.
Application Insights:
The drugs store segment held the largest share of 77.4% in 2017. Ulcerative colitis treatment drugs are expensive as they require a prescription and hence, people with ulcerative colitis prefer to buy them from a pharmacy instead of going to hospital or clinics for purchasing these medicines. As there is no cure available for this disease, patients are advised to take preventive measures while buying generic medicines as they do not have any insurance coverage and hence will have financial constraints while purchasing such medicines from a pharmacy.
Drug stores accounted for the highest share owing to availability of cheaper prices compared with other application segments like hospital, clinic or even others where these medications can be purchased over-the-counter (OTC).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of ulcerative colitis and other associated conditions, rising awareness about treatment options, availability of a large patient pool and high healthcare expenditure.
Asia Pacific is estimated to be the fastest-growing regional market from 2018 to 2030 owing to improving economic status & lifestyle habits in developing countries such as India & China. Moreover, an increase in disposable income levels will boost demand for medicines that treat ulcerative colitis over the forecast period. Furthermore, government initiatives are being undertaken by various countries for creating awareness about IBD treatments and their respective side effects are expected favorably impact growth prospects during the projected time frame.
Growth Factors:
- Increasing incidence of Ulcerative Colitis
- Growing awareness about Ulcerative Colitis Treatment options
- Rising demand for better and more effective therapies
- Technological advancements in the field of Ulcerative Colitis Treatment
- Availability of government funding for research and development in the field of Ulcerative Colitis Treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Ulcerative Colitis Treatment Market Research Report
By Type
Anti-inflammatory Drugs, Immune System Suppressors, Other medications
By Application
Hospital, Clinic, Drugs Store, Others
By Companies
Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson, Bayer, AbbVie, Eli Lilly and Company, Amgen, Takeda Pharmaceuticals Company, Ferring Pharmaceuticals, InDeX Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
155
Number of Tables & Figures
109
Customization Available
Yes, the report can be customized as per your need.
Global Ulcerative Colitis Treatment Market Report Segments:
The global Ulcerative Colitis Treatment market is segmented on the basis of:
Types
Anti-inflammatory Drugs, Immune System Suppressors, Other medications
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drugs Store, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Roche
- Sanofi
- GSK
- AstraZeneca
- MSD
- Johnson & Johnson
- Bayer
- AbbVie
- Eli Lilly and Company
- Amgen
- Takeda Pharmaceuticals Company
- Ferring Pharmaceuticals
- InDeX Pharmaceuticals
Highlights of The Ulcerative Colitis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-inflammatory Drugs
- Immune System Suppressors
- Other medications
- By Application:
- Hospital
- Clinic
- Drugs Store
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ulcerative Colitis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ulcerative colitis treatment typically includes medications to control the inflammation and pain, as well as lifestyle changes such as diet and exercise. In some cases, surgery may be necessary to remove the colon or rectum.
Some of the key players operating in the ulcerative colitis treatment market are Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson, Bayer, AbbVie, Eli Lilly and Company, Amgen, Takeda Pharmaceuticals Company, Ferring Pharmaceuticals, InDeX Pharmaceuticals.
The ulcerative colitis treatment market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ulcerative Colitis Treatment Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Ulcerative Colitis Treatment Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Ulcerative Colitis Treatment Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Ulcerative Colitis Treatment Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Ulcerative Colitis Treatment Market Size & Forecast, 2020-2028 4.5.1 Ulcerative Colitis Treatment Market Size and Y-o-Y Growth 4.5.2 Ulcerative Colitis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Anti-inflammatory Drugs
5.2.2 Immune System Suppressors
5.2.3 Other medications
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drugs Store
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ulcerative Colitis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ulcerative Colitis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Anti-inflammatory Drugs
9.6.2 Immune System Suppressors
9.6.3 Other medications
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drugs Store
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Anti-inflammatory Drugs
10.6.2 Immune System Suppressors
10.6.3 Other medications
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drugs Store
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Anti-inflammatory Drugs
11.6.2 Immune System Suppressors
11.6.3 Other medications
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drugs Store
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Anti-inflammatory Drugs
12.6.2 Immune System Suppressors
12.6.3 Other medications
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drugs Store
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Anti-inflammatory Drugs
13.6.2 Immune System Suppressors
13.6.3 Other medications
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drugs Store
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ulcerative Colitis Treatment Market: Competitive Dashboard
14.2 Global Ulcerative Colitis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Roche
14.3.4 Sanofi
14.3.5 GSK
14.3.6 AstraZeneca
14.3.7 MSD
14.3.8 Johnson & Johnson
14.3.9 Bayer
14.3.10 AbbVie
14.3.11 Eli Lilly and Company
14.3.12 Amgen
14.3.13 Takeda Pharmaceuticals Company
14.3.14 Ferring Pharmaceuticals
14.3.15 InDeX Pharmaceuticals